{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:03:45Z","timestamp":1768464225093,"version":"3.49.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To identify the most important factors affecting physician decision-making regarding antiplatelet therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively gathered data from minor ischemic stroke patients with NIHSS scores \u2264 5 within 72 h of onset from 2010 to 2018. The population was divided into four groups by initial antiplatelet therapy: aspirin monotherapy (AM), dual antiplatelet therapy with aspirin and a loading dose of clopidogrel (clopidogrel loading dose of 300 mg on the first day; DAPT-ALC), dual antiplatelet therapy with aspirin and no loading dose of clopidogrel (clopidogrel 75 mg daily, no loading dose; DAPT-AUC), and clopidogrel monotherapy (CM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 1,377 patients were included in the analysis (excluding patients who accepted thrombolytic drugs, participated in other clinical trials, or had not used antiplatelet drugs). The mean \u00b1 S.D. age was 62.0 \u00b1 12.7 years; 973 (70.7%) patients were male. The four groups were AM (<jats:italic>n<\/jats:italic> = 541, 39.3%), DAPT-ALC (<jats:italic>n<\/jats:italic> = 474, 34.4%), DAPT- AUC (<jats:italic>n<\/jats:italic> = 301, 21.9%), and CM (<jats:italic>n<\/jats:italic> = 61, 4.4%). Patients receiving antiplatelet monotherapy were older than those receiving dual antiplatelet therapy (63.7\u201365.7 vs. 59.6\u201361.4 years), and the median initial systolic blood pressure level was higher in the DAPT-ALC group than in the other groups (all <jats:italic>P<\/jats:italic> &amp;lt; 0.05). Patients under 75 years old with an admission SBP lower than 180 mmHg, a history of AM, coronary heart disease, no history of intracerebral hemorrhage, stroke onset occurring after guideline recommendations were updated (the year of 2015), onset-to-arrival time within 24 h, and initial NIHSS score \u2264 3 were more likely to take DAPT-ALC than AM. Compared with DAPT-ALC, DAPT-AUC was associated with an initial SBP level lower than 180 mmHg, a history of smoking, hypertension, no history of ICH, previous treatment with antihypertensives, and onset year after the recommendations were updated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Many factors affect doctors' decisions regarding antiplatelet therapy, especially guidelines, age, admission SBP level, and hypertensive disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.937417","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T14:13:23Z","timestamp":1662041603000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Factors affecting physician decision-making regarding antiplatelet therapy in minor ischemic stroke"],"prefix":"10.3389","volume":"13","author":[{"given":"Tingting","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyuan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongle","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haimei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1055\/s-0038-1649503","article-title":"Global burden of stroke","volume":"38","author":"Katan","year":"2018","journal-title":"Semin Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.3760\/cma.j.cn112338-20201208-01390","article-title":"Trends of a burden on atherosclerotic cardiovascular disease and its related risk factors in China, 1990 to 2019","volume":"42","author":"Zhang MN Li","year":"2021","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A Guideline From the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"B5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3760\/cma.j.issn.0578-1426.2015.09.001","article-title":"High-risk non-disabling ischemic cerebrovascular events: a window of opportunity for stroke control","volume":"54","author":"Wang","year":"2015","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/1747493017694391","article-title":"2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack","volume":"12","author":"Wang","year":"2017","journal-title":"Int J Stroke"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ahj.2010.05.017","article-title":"Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event","volume":"160","author":"Wang","year":"2010","journal-title":"Am Heart J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1161\/STROKEAHA.119.026044","article-title":"Comparative effectiveness of dual antiplatelet therapy with aspirin and clopidogrel versus aspirin monotherapy in acute, nonminor stroke: a Nationwide, Multicenter Registry-Based Study","volume":"50","author":"Kim","year":"2019","journal-title":"Stroke"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1212\/WNL.0b013e3182a55ec7","article-title":"The complexities of acute stroke decision-making: a survey of neurologists","volume":"81","author":"Shamy","year":"2013","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1161\/STROKEAHA.114.005462","article-title":"Decision making in acute stroke care: learning from neuroeconomics, neuromarketing, and poker players","volume":"45","author":"Saposnik","year":"2014","journal-title":"Stroke"},{"key":"B13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12883-015-0480-4","article-title":"Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study","volume":"15","author":"Christiansen","year":"2015","journal-title":"BMC Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/WCO.0000000000000509","article-title":"Antiplatelet therapy after stroke: should it differ in the acute and chronic phase after stroke","volume":"31","author":"Leng","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1161\/STROKEAHA.119.024786","article-title":"Dual versus mono antiplatelet therapy in large atherosclerotic stroke","volume":"50","author":"Kim","year":"2019","journal-title":"Stroke"},{"key":"B16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/svn-2016-000008","article-title":"Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial","volume":"1","author":"Wang","year":"2016","journal-title":"Stroke Vasc Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtypeof acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1161\/STROKEAHA.120.031707","article-title":"Stroke prevention in older adults: recent advances","volume":"51","author":"Spence","year":"2020","journal-title":"Stroke"},{"key":"B19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.11909\/j.issn.1671-5411.2019.02.006","article-title":"Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes","volume":"16","author":"De Rosa","year":"2019","journal-title":"J Geriatr Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"661619","DOI":"10.3389\/fphar.2021.661619","article-title":"Incidence and risk factors for antiplatelet therapy-related bleeding complications among elderly patients after coronary stenting: a multicenter retrospective observation","volume":"12","author":"Qian","year":"2021","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.amjcard.2019.07.006","article-title":"Consensus clinical decision-making factors driving anticoagulation in atrial fibrillation","volume":"124","author":"King","year":"2019","journal-title":"Am J Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1161\/STROKEAHA.119.026316","article-title":"Intensive blood pressure treatment reduced stroke risk in patients with albuminuria in the SPRINT trial","volume":"50","author":"Leitao","year":"2019","journal-title":"Stroke"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/svn-2016-000057","article-title":"Determinants of the impact of blood pressure variability on neurological outcome after acute ischaemic stroke","volume":"2","author":"de Havenon","year":"2017","journal-title":"Stroke Vasc Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2112551","DOI":"10.1001\/jamanetworkopen.2021.12551","article-title":"Evaluation of systolic blood pressure, use of aspirin and clopidogrel, and stroke recurrence in the platelet-oriented inhibition in new TIA and minor ischemic stroke trial","volume":"4","author":"de Havenon","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B25","doi-asserted-by":"publisher","first-page":"CD012144","DOI":"10.1002\/14651858.CD012144.pub2","article-title":"Antithrombotic treatment after stroke due to intracerebral haemorrhage","volume":"5","author":"Perry","year":"2017","journal-title":"Cochr Database Syst Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e695","DOI":"10.1212\/WNL.0000000000007935","article-title":"Effect of coexisting vascular disease on long-term risk of recurrent events after TIA or stroke","volume":"93","author":"Boulanger","year":"2019","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1161\/STROKEAHA.115.011595","article-title":"Different antiplatelet strategies in patients with new ischemic stroke while taking aspirin","volume":"47","author":"Kim","year":"2016","journal-title":"Stroke"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0230446","DOI":"10.1371\/journal.pone.0230446","article-title":"Physician decision-making and recommendations for stroke and myocardial infarction treatments in older adults with mild cognitive impairment","volume":"15","author":"Levine","year":"2020","journal-title":"PLoS ONE"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.mayocp.2018.01.028","article-title":"Propensity score matched comparison of clinical outcomes in atrial fibrillation patients taking vitamin K antagonists: comparing the \u201creal-world\u201d vs clinical trials","volume":"93","author":"Rivera-Caravaca","year":"2018","journal-title":"Mayo Clin Proc"}],"updated-by":[{"DOI":"10.3389\/fneur.2022.1053112","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000}}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.937417\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T08:36:41Z","timestamp":1665736601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.937417\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":29,"alternative-id":["10.3389\/fneur.2022.937417"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.937417","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fneur.2022.1053112","asserted-by":"object"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"article-number":"937417"}}